LQDA

Liquidia Corporation (LQDA) | Rumor.io

Liquidia

LQDA

Attention (50-day avg)0.01%

Attention rank (50-day avg)#381

Bullish sentiment (50-day avg)70%

Price to earnings ratio48.9

Market capitalization6.6B

Earnings per share1.4

Dividend yield (TTM)—

Revenue (annual)158.3M

Net income (annual)-68.9M

Social

What share of all stock conversation is about LQDA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% 0	0.01% +0	0.01% -0.01	0.01% +0

Sep 28

$LQDA is expected to rebound from September's lows, with one brokerage anticipating a ruling in Q3.
The company's share price has been gaining momentum, with one report noting it's "rapidly gaining share."
$LQDA's earnings are not due for another 5 weeks, but its price is being influenced by speculation and trading, with one post noting it's "testing $71.21 from below on light volume."

Generated by AI

Sentiment

Of the messages about LQDA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	76.47% +13.61	47.09% -12.68	72.73% +4.17	76.67% +3.18
Bearish	23.53% -13.61	52.91% +12.68	27.27% -4.17	23.33% -3.18

Bullish· Aug 13

Liquidia Corporation's Q2 results were fundamentally positive, with the company delivering solid earnings and a solid outlook for the future.
The company's success has led to a significant increase in market share, with many analysts and institutions taking a bullish stance on the stock, citing its strong growth potential.
Despite a recent decline, many experts believe that Liquidia Corporation's stock will rebound and potentially reach new all-time highs, with some analysts even predicting a price of $130.86 over the next 52 weeks.

Bearish· Aug 2

Liquidia Corporation's earnings are due on August 12, which could impact the stock price negatively.
The stock has broken out of a tight flag formation, but the 82.96 pivot level is being tested, indicating potential weakness.
The company's EPS (earnings per share) is expected to drop on August 12, which could be a bearish indicator for the stock.

Generated by AI

Topics

Of the messages about LQDA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	38.68%	60.15%	40.81%
Technical Analysis	100%	9.43%	12.69%	12.21%
Controversies	0%	0%	12.69%	18.43%
Analysts	0%	51.89%	14.47%	9.04%
Earnings	0%	0%	0%	19.13%
Macro	0%	0%	0%	0.39%

Earnings· May 11

Liquidia Corporation reported Q1 2026 earnings of $0.52 per share, beating the FactSet consensus of $0.41.
Revenue for Q1 2026 was $132.9 million, a 4,160% increase year-over-year, beating the FactSet consensus of $119.4 million.
The company's YUTREPIA product achieved net sales of $129.9 million in Q1 2026, with over 4,500 unique patient prescriptions and approximately 3,750 patients treated since its launch in June 2025.

Announcements· May 11

Liquidia Corporation's Q1 2026 earnings show YUTREPIA launch achieving hyper-growth, with net product sales of approximately $130 million.
The company reported strong Q1 results, including a beat on both top and bottom line, driven by YUTREPIA revenue growth, with over 4,500 unique patient prescriptions and 3,750 patients treated since launch.
Liquidia's Q1 2026 results confirm YUTREPIA's successful specialty pharma launch, with accelerating total revenue and massive profitability, but scaling costs and ongoing patent litigation with United Therapeutics pose risks to commercialization.

Technical Analysis· Aug 2

$LQDA is pulling back to test the 82.96 pivot from its tight flag, two weeks after the breakout, with earnings due 8/12 before the open.
The stock's tight flag formation suggests a potential reversal, with the 82.96 pivot level being closely watched after the breakout two weeks ago.
$LQDA's pullback is being closely monitored as it retests the 82.96 pivot level, with earnings expected to be released on 8/12 before the market open.

Generated by AI

Community

Of the messages about LQDA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	94.12%	84.64%	84.75%	80.48%
Newcomers	5.88%	15.36%	15.25%	19.52%

Regulars· Sep 28

Analyst models indicate $LQDA is undervalued and has significant upside potential.
A brokerage expects a ruling in Q3, but it's uncertain when it will come, and the company is working to make it "bulletproof".
$LQDA is rapidly gaining share, and the author is optimistic about its prospects.

Newcomers· Aug 13

Many newcomers are buying Liquidia Corporation's stock despite its recent 18% drop, expecting a bounce.
New investors are focusing on the company's fundamentals, such as its forecasted downturn and the mom indicator, which may have been triggered.
Some newcomers are citing analyst upgrades and price targets, with Jefferies predicting a price of $115 and investors encouraging others to buy, calling the correction "waay overblown".

Generated by AI

News

Liquidia: high growth, demanding valuation in mid-cap space

16h agoInvesting.com

Liquidia rises 8% amid broader strength in biotech peers (LQDA:NASDAQ)

1d agoSeeking Alpha

United Therapeutics: The Market Sees The Erosion, Not The Refill - Buy (NASDAQ:UTHR)

United Therapeutics' declines are real but they sit in ~32% of the business, tax-normalized earnings power is $1.05 billion. See why UTHR stock is a Buy now.

2d agoSeeking Alpha

LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?

Liquidia's Yutrepia is gaining traction, but patent litigation, competition, rising costs and heavy product dependence cloud LQDA's outlook.

18d agoYahoo Finance

Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?

Liquidia's Yutrepia wins FDA Fast Track status for SSc-related Raynaud's, opening a potential new growth avenue for the lead drug.

19d agoYahoo Finance

Liquidia at Wells Fargo 21st annual healthcare conference: growth and pipeline

21d agoInvesting.com

Also Discussed

Investors talking about LQDA also mention

#	Name	Attention
1	United Therapeutics CorporationUTHR	0%-0.01
2	Movella Holdings Inc.MVLA	0%0
3	Insmed IncorporatedINSM	0%new
4	Richardson Electronics, Ltd.RELL	0%0
5	Hinge Health Inc.HNGE	0.01%+0
6	VRNA - Verona Pharma plc	——
7	Abivax SAABVX	0.01%-0.01
8	Eton Pharmaceuticals, Inc.ETON	0%-0.01
9	Ani Pharmaceuticals, Inc.ANIP	0%new
10	Brookfield Business Corporation Class A Subordinate Voting SharesBBUC	0%-0.01

Liquidia Corporation

Healthcare
Biotechnology

Liquidia Corporation is a biopharmaceutical company focused on developing, manufacturing, and commercializing therapies for rare cardiopulmonary diseases. The company’s current portfolio centers on treatments for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, supported by its proprietary PRINT particle-engineering platform, which is designed to create precise drug particles for inhaled and other advanced delivery formats. Liquidia’s work spans product development, manufacturing, and commercialization, giving it a role across the full lifecycle of specialty respiratory medicines. Its marketed and investigational programs are aimed at patients with challenging respiratory and vascular conditions, positioning the company within the rare-disease and specialty pharmaceutical markets. Liquidia Corporation is headquartered in Morrisville, North Carolina.

Website

Location

419 Davis Drive

Morrisville, NC, 27560

United States

Social

What share of all stock conversation is about LQDA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% 0	0.01% +0	0.01% -0.01	0.01% +0

Sep 28

$LQDA is expected to rebound from September's lows, with one brokerage anticipating a ruling in Q3.
The company's share price has been gaining momentum, with one report noting it's "rapidly gaining share."
$LQDA's earnings are not due for another 5 weeks, but its price is being influenced by speculation and trading, with one post noting it's "testing $71.21 from below on light volume."

Generated by AI

Sentiment

Of the messages about LQDA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	76.47% +13.61	47.09% -12.68	72.73% +4.17	76.67% +3.18
Bearish	23.53% -13.61	52.91% +12.68	27.27% -4.17	23.33% -3.18

Bullish· Aug 13

Liquidia Corporation's Q2 results were fundamentally positive, with the company delivering solid earnings and a solid outlook for the future.
The company's success has led to a significant increase in market share, with many analysts and institutions taking a bullish stance on the stock, citing its strong growth potential.
Despite a recent decline, many experts believe that Liquidia Corporation's stock will rebound and potentially reach new all-time highs, with some analysts even predicting a price of $130.86 over the next 52 weeks.

Bearish· Aug 2

Liquidia Corporation's earnings are due on August 12, which could impact the stock price negatively.
The stock has broken out of a tight flag formation, but the 82.96 pivot level is being tested, indicating potential weakness.
The company's EPS (earnings per share) is expected to drop on August 12, which could be a bearish indicator for the stock.

Generated by AI

Topics

Of the messages about LQDA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	38.68%	60.15%	40.81%
Technical Analysis	100%	9.43%	12.69%	12.21%
Controversies	0%	0%	12.69%	18.43%
Analysts	0%	51.89%	14.47%	9.04%
Earnings	0%	0%	0%	19.13%
Macro	0%	0%	0%	0.39%

Earnings· May 11

Liquidia Corporation reported Q1 2026 earnings of $0.52 per share, beating the FactSet consensus of $0.41.
Revenue for Q1 2026 was $132.9 million, a 4,160% increase year-over-year, beating the FactSet consensus of $119.4 million.
The company's YUTREPIA product achieved net sales of $129.9 million in Q1 2026, with over 4,500 unique patient prescriptions and approximately 3,750 patients treated since its launch in June 2025.

Announcements· May 11

Liquidia Corporation's Q1 2026 earnings show YUTREPIA launch achieving hyper-growth, with net product sales of approximately $130 million.
The company reported strong Q1 results, including a beat on both top and bottom line, driven by YUTREPIA revenue growth, with over 4,500 unique patient prescriptions and 3,750 patients treated since launch.
Liquidia's Q1 2026 results confirm YUTREPIA's successful specialty pharma launch, with accelerating total revenue and massive profitability, but scaling costs and ongoing patent litigation with United Therapeutics pose risks to commercialization.

Technical Analysis· Aug 2

$LQDA is pulling back to test the 82.96 pivot from its tight flag, two weeks after the breakout, with earnings due 8/12 before the open.
The stock's tight flag formation suggests a potential reversal, with the 82.96 pivot level being closely watched after the breakout two weeks ago.
$LQDA's pullback is being closely monitored as it retests the 82.96 pivot level, with earnings expected to be released on 8/12 before the market open.

Generated by AI

Community

Of the messages about LQDA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	94.12%	84.64%	84.75%	80.48%
Newcomers	5.88%	15.36%	15.25%	19.52%

Regulars· Sep 28

Analyst models indicate $LQDA is undervalued and has significant upside potential.
A brokerage expects a ruling in Q3, but it's uncertain when it will come, and the company is working to make it "bulletproof".
$LQDA is rapidly gaining share, and the author is optimistic about its prospects.

Newcomers· Aug 13

Many newcomers are buying Liquidia Corporation's stock despite its recent 18% drop, expecting a bounce.
New investors are focusing on the company's fundamentals, such as its forecasted downturn and the mom indicator, which may have been triggered.
Some newcomers are citing analyst upgrades and price targets, with Jefferies predicting a price of $115 and investors encouraging others to buy, calling the correction "waay overblown".

Generated by AI

Liquidia

Social

Sep 28

Bullish· Aug 13

Bearish· Aug 2

Earnings· May 11

Announcements· May 11

Technical Analysis· Aug 2

Regulars· Sep 28

Newcomers· Aug 13

Liquidia: high growth, demanding valuation in mid-cap space

Liquidia rises 8% amid broader strength in biotech peers (LQDA:NASDAQ)

United Therapeutics: The Market Sees The Erosion, Not The Refill - Buy (NASDAQ:UTHR)

LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?

Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?

Liquidia at Wells Fargo 21st annual healthcare conference: growth and pipeline

Also Discussed

Liquidia Corporation

Company Information

Location

Liquidia: high growth, demanding valuation in mid-cap space

Liquidia rises 8% amid broader strength in biotech peers (LQDA:NASDAQ)

United Therapeutics: The Market Sees The Erosion, Not The Refill - Buy (NASDAQ:UTHR)

LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?

Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?

Liquidia at Wells Fargo 21st annual healthcare conference: growth and pipeline

Also Discussed

Social

Sep 28

Bullish· Aug 13

Bearish· Aug 2

Earnings· May 11

Announcements· May 11

Technical Analysis· Aug 2

Regulars· Sep 28

Newcomers· Aug 13